Mechanostics®
Mechanism-based precision medicine tests for chronic diseases
First-in-class genotypic tests to accurately determine disease risk, mechanistic causes, and most effective treatments for patients
For research use only. Not for use in diagnostic procedures.
Mechanostics benefits for providers:
1. Personalized Treatment Guidance
Mechanostics identify disease mechanisms, helping tailor interventions to individual patient needs.
2. Clearer Clinical Decision-Making
Simplifies diagnosis and accelerates triage of overlapping symptom conditions, reducing time to treatment.
3. Practical in Routine Care
Delivered via non-invasive samples, usable in primary care or at home without specialist infrastructure.
4. Earlier, Better Outcomes
Enables proactive care by identifying risks before severe symptoms develop - saving clinician time and improving patient quality of life.
Mechanostics allow payors to:
1. Reduce Costs of Care
Early risk prediction and stratification lowers unnecessary treatments and hospitalizations, reducing spend.
2. Promote Health Equity
Common variant combinations improve predictive accuracy across diverse ancestries and populations.
3. Streamline Diagnosis
Low-cost, non-invasive testing supports efficient triage and reduces burden on healthcare systems.
4. Enable Reimbursement
Demonstrated precision in stratification supports long-term cost savings and payer adoption.
Mechanostics offer diagnostics providers:
1. Access to Major Unaddressed Markets
Mechanostics target underserved chronic conditions responsible for over 80% of healthcare costs - unlocking large new diagnostic markets.
2. Scalable Revenue Growth
High-prevalence conditions support recurring revenues via self-pay and licensing models across a global patient base.
3. Easy Lab Deployment
Tests use standard genotyping platforms already in CLIA labs worldwide - enabling rapid, low-cost global rollout.
4. Competitive Differentiation
Outperform polygenic/metabolomic tests with disease-specific triage and mechanistic insight - creating real product advantage.
Mechanostics benefits for patients:
1. Faster, More Accurate Diagnosis
Mechanostics uncover the root cause of symptoms, reducing diagnostic delays and misdiagnoses in complex chronic conditions.
2. Personalized, Effective Treatments
By revealing each patient’s specific disease mechanisms, tests support therapies that are more likely to work and less likely to cause harm.
3. Convenient and Non-Invasive
Tests are simple, saliva-based, and can be taken at home or in a primary care setting – no hospital visits or invasive procedures required.
4. Empowered, Preventive Care
Mechanostics identify risk before disease develops, enabling patients to take proactive steps and work with their care teams to stay healthier, longer.
Tab heading
Mechanostics benefits for providers:
1. Personalized Treatment Guidance
Mechanostics identify disease mechanisms, helping tailor interventions to individual patient needs.
2. Clearer Clinical Decision-Making
Simplifies diagnosis and accelerates triage of overlapping symptom conditions, reducing time to treatment.
3. Practical in Routine Care
Delivered via non-invasive samples, usable in primary care or at home without specialist infrastructure.
4. Earlier, Better Outcomes
Enables proactive care by identifying risks before severe symptoms develop - saving clinician time and improving patient quality of life.
Mechanostics allow payors to:
1. Reduce Costs of Care
Early risk prediction and stratification lowers unnecessary treatments and hospitalizations, reducing spend.
2. Promote Health Equity
Common variant combinations improve predictive accuracy across diverse ancestries and populations.
3. Streamline Diagnosis
Low-cost, non-invasive testing supports efficient triage and reduces burden on healthcare systems.
4. Enable Reimbursement
Demonstrated precision in stratification supports long-term cost savings and payer adoption.
Mechanostics offer diagnostics providers:
1. Access to Major Unaddressed Markets
Mechanostics target underserved chronic conditions responsible for over 80% of healthcare costs - unlocking large new diagnostic markets.
2. Scalable Revenue Growth
High-prevalence conditions support recurring revenues via self-pay and licensing models across a global patient base.
3. Easy Lab Deployment
Tests use standard genotyping platforms already in CLIA labs worldwide - enabling rapid, low-cost global rollout.
4. Competitive Differentiation
Outperform polygenic/metabolomic tests with disease-specific triage and mechanistic insight - creating real product advantage.